With Antisense Rx Already in Phase I, Bio-Path Eyes RNAi Rx Market
July 21, 2011
With Antisense Rx Already in Phase I, Bio-Path Eyes RNAi Rx Market
The company hopes phase I data from the antisense candidate will confirm the efficacy of its proprietary delivery technology and help it secure capital and biopharma partnerships to advance an siRNA-based cancer therapeutic into the clinic.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Primate Testing on Deck, nLife Aims at Partnerships for Neuron Delivery Technology
February 28, 2013 / Gene Silencing News - Alnylam Forms Alliance with Genzyme in ATTR, Adds Another Notch to Partnership Belt
October 25, 2012 / Gene Silencing News - UT Southwestern Team Publishes Details on Duplex RNA Inhibition of Huntington's Disease Gene
October 18, 2012 / Gene Silencing News - Isis Studies Suggest Therapeutic Potential of Single-Stranded RNAi Molecules
September 6, 2012 / Gene Silencing News - Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012 / Gene Silencing News